Mr. Gil-Ad brings more than 25 years of experience in management of large R&D projects. Prior to founding NovellusDx, Haim Gil-Ad was the CEO of Optigo Systems Ltd., a vertically integrated high-tech company developing technology-oriented products and a leader in electro-optical R&D that was acquired by the Elta Co. of Israel Aerospace Industries. Prior to joining Optigo, Mr. Gil-Ad pursued an extensive career with the Israeli Ministry of Defense (IMOD) as head of major international R&D and full-scale development programs. Mr. Gil-Ad earned a B.Sc. in Engineering from Tel-Aviv University and an MBA from Ben-Gurion University. He has twice been awarded the Israel National Quality Award.
Director, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
From 2013, Jelena has been positioned as Acting Director of the Institute of Molecular Genetics and Genetic Engineering, at the University of Belgrade and from 2016 Head of the Laboratory for Molecular Microbiology, IMGGE.
Her research focus is on fundamental research in the field of molecular microbiology and also on the application of biotech in food and pharmaceutical industry. She has particular expertise in research related to lactic acid bacteria (LAB) and their probiotic potential and mechanisms of antibiotic resistance in different microorganisms. Jelena has published more than 50 papers in leading international journals in the field.
From 2013 she has been involved as a Lecturer in the Faculty of Pharmacy in a doctoral study program Microbiology and Immunology.
In 2016 she established the Technology Transfer Office in IMGGE and she is actively involved in all activities related to technology transfer. In addition, through intensive collaboration with industry she is focused on implementation of open innovation concepts both within the Institute and in the country. She is a coordinator and participant in numerous scientific and innovative national and international projects including those with the industry.
Business Model Generation, Running Lean Coach & Start-up Mentor
Domen Bole is a founder and managing director of Co-creation, providing key expertise in the start-ups, entrepreneurship and innovation ecosystem development, and he acts as advisor to top management of Business Incubator of University of Ljubljana and supports the development of teams and start-ups coming mainly from academia.
As seasoned startup coach and mentor with 10+ years of experience, Domen helps early stage startups develop and validate their business models and raise funds using running lean methodology. He has supported over 400 startups within startup competitions, acceleration programs, startup incubators, technology parks in South eastern Europe.
All together Domen has more than 20 years of international professional experience as research assistant, founder of start-ups, interim manager in SMEs and corporate entrepreneur with investment fund experience. He has extensive global network with masters focused in Entrepreneurship and certifications in Intellectual Property Valuation and Technology Transfer. He is also a co-author of SEE Startup Report 2018 and several other publications in field of startup ecosystem development.
Areas of Expertise:
• Early stage Business model development
• Running lean methodology
• Found raising & pitching
• Seed investments
Nicolas Charton is the co-founder and managing director of E-CUBE Strategy Consultants SA in Lausanne, which specialises in the energy and mobility sectors. An engineer with expertise in industrial organisation, he advises the top management of major Swiss and European energy companies, and public bodies.
David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of post-doctoral experience. David has worked in the pharmaceutical industry for almost 20 years. He worked in big pharma at AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. Whilst at AstraZeneca he was heavily involved in developing the use of informatics and systems biology to support the development of new medicines. David joined Blueberry Therapeutics as Chief Scientific Officer at the start of 2014. In this role, he is responsible for leading the research activities of the business which are focused on developing new treatments for serious infectious diseases. The first of these treatments has now entering clinical testing.
Julie is an Associate Director at Endless Frontier Labs, a nine-month mentorship program for highly scalable life science and technology startups. She brings 7 years of bench science, healthcare management consulting, and pharma equity research experience to her current role at EFL. Julie also has experience in seed-stage life science investing, where she developed a passion for startups and expanding opportunities for founders to grow their businesses. Julie holds a Ph.D. in Pathology from NYU School of Medicine, where she studied immunotherapy and radiation for the treatment of cancer.
Clinical Lead Director & Country Manager Serbia, IQVIA
Dr Lara Dobrkovic is Clinical Lead Director and Country Manager for Serbia in IQVIA, one of the leading CRO companies in the world. She is managing group of Clinical Leads around the world; and overseeing dozens of clinical studies for new medicines in Central Nervous System and Gastro-Intestinal system. Prior to taking role in management and oversight, she worked herself for few years as leader of big, multicentric and international projects in various indications, and started her carrier in clinical research as Clinical Research Associate working closely with biggest hospitals in Serbia. Overall, she has over than 15 years of Pharmaceutical industry experience, with the last 12 years in management and leadership positions of various departments within the company.
She graduated from Faculty of Medicine in Belgrade and obtained academic specialization in Pharmaceutical Medicine. She speaks fluent English and Spanish, and has medium level knowledge of German. In her free time, she is inclined to all kinds of sports activities.
Jim Doherty is passionate about helping businesses to grow.
Based at Inventya and having lead delivery on the successful Scaleup Programme Pilot, Jim is now integral to the Scaleup Programme delivery function. He coordinates the operational client service offer as well as managing a significant client portfolio.
A corporate finance specialist and experienced board- level finance professional, he has over 25 years’ experience contributing to the financial strategic direction of numerous fast growth SMEs.
Jim started a lift manufacturing company in his late twenties which grew to a £2m-turnover, 45-employee enterprise within 18 months, winning contracts with global corporations such as Thyssen, Kone, Otis, Fujitec, Mitsubishi and Schindler.
Jim has considerable experience engaging with and presenting to the VC community, leading several funding rounds for both established and growing as well as early stage and pre-revenue businesses within the telecommunications, manufacturing, service and facilities management, legal medical services, mobile data recovery and cybersecurity, biopharma and medical device sectors.
Martin Eglitis, Ph.D., has over 15 years research experience and additionally 20 years of pharmaceutical licensing experience. He has headed labs at the NIH, lead discovery and enablement research teams at a biotech startup, and conducted all aspects of the licensing process at global pharmaceutical companies. Dr. Eglitis has closed licensing deals valued into the hundreds of millions of dollars. Currently at Blazing Star Pharma Advisors, he provides strategic and business development consulting services to small and mid-size biopharmaceutical companies.
Prior to founding Blazing Star Pharma Advisors, Dr. Eglitis held Senior Business Development positions at Teva Pharmaceutical Industries Ltd., Amgen Inc., and Eli Lilly and Company. Dr. Eglitis was also involved in one of the first gene therapy start-ups, Genetic Therapy Inc., from its inception through a successful IPO. While there he contributed to the IND filing for the first gene therapy clinical trial.
Dr. Eglitis is inventor on four patents, and author of dozens of research papers and book chapters, spanning a wide breadth of fields including mammalian developmental biology, retroviral vector molecular biology, and physiological responses to neurological disease and injury. He obtained his baccalaureate in Biology and Ph.D. in Anatomy and Developmental Biology from the University of Virginia.
Amy Fan is passionate about bringing a human-centric approach to healthcare. She is the Co-founder of Twentyeight Health, a digital women's health platform focused on increasing access to reproductive and sexual health for underserved communities. Combining telemedicine, prescription delivery, and technology, Twentyeight health improves convenience, access and adherence.
Previously, Amy was the General Manager of Onomie Beauty, a direct-to-consumer beauty venture that combines makeup impact with clinically-proven skincare efficacy. She immersed herself in learning about the needs, pain points and aspirations of different women to develop Allure Best of Beauty award winning products. Prior to Onomie, Amy was a consultant at Bain & Company. Amy holds an MBA and a Masters of Public Health from the University of California Berkeley, and a Bachelor of Commerce from Queen's University.
Marissa Fayer is a 20-year medtech executive, entrepreneur, and philanthropist. She is the CEO and founder of social enterprise HERHealthEQ and the president of advisory firm Fayer Consulting LLC,. Her mission is to move innovation and the health of women forward throughout the world through the advancement of organizations and the communities in which they operate by increasing investment, building world-class organizations and healthcare systems, and enhancing partnerships.
Marissa has previously served as an executive at Hologic, Olympus (formerly ACMI), Maquet-Getting (formerly Atrium Medical), Providien Medical, and Accumed Innovative Technologies. Her consulting clients include several of the Top 500 companies in the world and innovative start-ups. Marissa sits on the board of medtech companies Welwaze Medical and DeepLook, both focused on improving the diagnosis of breast cancer. Marissa graduated from Boston University with a BS in Manufacturing Engineering and from University of Connecticut with an MBA.
Marissa is a TEDx Speaker (2019 at TEDxLugano), and has been listed as one of the Top 100 Women in Medtech in 2018, a Top Woman Activist to Watch, awarded the 2018/9 Africa Development Award, and a Wonder Women in Medtech in 2017. Marissa leads the #wealththroughhealth and #healthequityforwomen movements and is dedicated to moving women’s health forward throughout the world.
Marissa lives in New York City and can be found at www.marissafayer.com
Aldo is working in line with Business’ CEOs and CTOs, making decisions and reaching successful conclusions with regard to digital technologies.
He possesses extensive client facing experience in B2B and B2C and continues to be a confident manager across different countries for large web development teams, as well as for outsourcing companies. Aldo demonstrates natural ability in organising teams, client and projects, making the process run perfectly for large organisations, without the hassle of technicalities.
He has an ongoing long-standing experience in helping startups as a mentor & coach and he continues to collaborate with venture.ch (EPFL - ETH), masschallenge.com, fusion.xyz and other accelerators.
Yoon-Chi is a research project leader at Pfizer Oncology R&D developing contemporary oncology and immune-oncology drugs such as biotherapeutics, nanoparticles and antibody-drug conjugates. For the past 5 years, she has led projects from target discovery to clinic as well as several exploratory programs. She also established and managed external collaborations with academic institutions. Prior to her role in industry she was a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center focusing on cancer biology and genetics. She obtained her Ph.D. in immunology from Columbia University.
Sina Henrichs has broad professional experience in implementation and development of projects in research-driven environments. She holds a doctorate in Molecular Biology from the University of Zurich as well as an MBA in Academic Management form the University of Basel. Sina Henrichs combines her extensive research experience in the life sciences and in-depth understanding of process development and project management to provide interactive and professional training experiences. She implemented the Graduate Center GRACE, the professional platform for doctoral candidates and postdocs at the University of Basel and is founder of Manage Science (www.managescience.ch). Since 2018, Sina is working as Project Manager Education at the AO Foundation in Davos.
Nick is a co-founder and CEO of Accunea Ltd, a medical device company with real time diagnostic monitoring products for patients with AKI and is the Director of Precision Medicine Strategy for New Medicine Partners, UK.
Nick has a PhD in Microbial Genetics from University of Warwick followed by post graduate research (genomics/biotechnology) at Harvard (DFCI, 1995) and Oxford (Biochemistry, 2000). At Oxford, the research in Professor Sir Ed Southern’s laboratory led to the creation of the spin out company Oxford Gene Technology Limited. Nick went on to secure a fellowship in technology transfer at the University of Warwick and then to Manchester as a business consultant to UMIC, mentoring entrepreneurs and commercial development of the bioincubator. This was followed by heading up the business group at Warwick HRI (2008) and the creation of Warwick Enterprise Park for provision of incubation facilities. Nick held several senior level positions as Scientist, CEO, NED, investor and Chairman in several start up enterprises such as the Oxford University start-up Oxagen (Human Genetics, 2003) Novolytics (antimicrobial therapeutics, 2010), BioMimox (peptide aptamers, 2014), Arcamis (business consulting, 2010), and has served as the Director of Business Development at OBN (2012). Nick has raised significant public, private, VC and business angel funding (Beer and Partners, 2013) for several businesses (multiple £M) and was a coach for the Growth Accelerator programme. More recently Nick created the Molecular Diagnostics Centre within the John Radcliffe Hospital, Oxford, building self-sustainability models and international collaborations and partnerships. Nick also led the successful bid to become the Oxford Genomics Medicine Centre and the Director of the Programme. Nick is a current member of the Diagnostics Advisory Council in Oxfordshire; has advised on Genomics products for ThermoFisher; was a lecturer at MIB (Manchester) in genomics; and graduated (2016) with a PGDiP in Strategy and Innovation from the Said Business School in Oxford.
Janko Ignjatović holds a master of pharmacy degree from the Faculty of Pharmacy, University of Belgrade in Serbia. Upon finishing master studies, he continued his academic and scientific development by enrolling in doctoral studies at the module of Drug Analysis at the Faculty of Pharmacy, University of Belgrade, Serbia.
Moreover, his curiosity and motivation to contribute to science and healthcare led him to further expand his expertise and professional development within pharmaceutical companies GSK and Novartis. Furthermore, during his postgraduate development he was declared as individual winner of Regional BioCamp, a forum connecting academics and industry in Ljubljana capital of Slovenia, thus he gained the right to participate in the Global BioCamp which was organized in headquarters of pharmaceutical company Novartis in Basel, Switzerland. There he was selected as an individual winner of the global Novartis BioCamp 2014. For this achievement he was awarded a professional training and a visit at Novartis Institute for Biomedical Research (NIBR) in Beijing and Shanghai in the People's Republic of China.
Motivated to continue with his passion to foster application of academic knowledge in the industrial field and give his contribution to shaping the healthcare, he pursued a career of research scientist in Novartis global drug development department for biopharmaceutical drugs in Mengeš, Slovenia.
In addition to working in pharmaceutical industry, he enrolled and completed an additional doctorate studies in the field of Biotechnology of the Biotechnical Faculty, University of Ljubljana, where the primary focus of his research is protein aggregation and its potential immunogenicity.
Janko continued with further personal and professional development in the field of management, leadership, economics and project management within courses in prestigious International Executive Development Centre (IEDC) in Bled, Slovenia. Currently, he is attending Masters in Business Administration (MBA) studies at the Faculty of economics and centre for business excellence in Ljubljana, Slovenia.
Dr Drago Indjic is a Managing Director at Oxquant. Oxquant provides expertise and advice on risk management, investments and the impact of data science and artificial intelligence in finance and other knowledge-based industries. Drago is also a co-founder and an adviser to several technology and fund businesses across Europe; has been an EU technology project funding evaluator since 1997; and lectures on fintech and hedge funds. Drago has over 25 years’ experience in alternative investments and entrepreneurship; and has worked as a portfolio manager and in research at several hedge funds, a family office and for a sovereign wealth fund. Drago holds a Dipl Ing from the University of Belgrade and a PhD from Imperial College, London.
Daniel Jamieson is the CEO and founder of Biorelate. He founded Biorelate during his PhD in computational biology at the University of Manchester, UK, after supporting the successful development of drug re-purposing opportunities with Pfizer. Over the last 6 years Daniel has overseen the growth of a blooming global business backed by VC investment of over £1M, with over 25 employees and a growing range of major industrial players on-board as clients. Biorelate is now recognised as one of the breakthrough AI drug discovery companies and Daniel’s focus remains on growing it into a world leading enterprise, helping pioneering companies in developing the innovations of the future.
Mark Kaplan is a seasoned researcher in the Biopharma Industry. He graduated Summa Cum Laude from Harvard College with an AB in Biochemistry and from the University of California, San Francisco with a PhD in Biophysics. He subsequently was a Leukemia Society Postdoctoral Fellow at the University of Wisconsin, but then he heard the siren call of industry. Mark has had diverse experiences in biopharma: traditional pharma settings (Pfizer, Roche), mid-size biotechs (Deltagen, Exelixis, Celera Genomics), academic-industry partnerships (Pfizer's CTI unit), a 19 person startup (Quentis Therapeutics). Mark spent many years as a discovery scientist - discovering new drug targets, developing new technologies, and leading early stage programs – and more recently has migrated to Translational Research, learning how to apply learnings from the lab to clinical medicine. He is currently working on a Medical Countermeasures project to mitigate against Radiation and Chemical injuries.
Paul is co-founder and Chief Executive Officer of HairClone, a cell therapy Company developing cell based treatments for androgenic alopecia. Paul has over 30 years’ experience in the US and UK in the commercialisation of various Regenerative Medicine and Cell Therapy products in both public and private Companies. He was the lead inventor on patents for Apligraf the first multi-cell therapy approved by the FDA which has treated hundreds of thousands of patients in the US with chronic ulcers. Paul was the sole founder of Intercytex Ltd. where he served as CEO for the first 5 years. During this period Intercytex developed several products that reached the clinic, including Vavelta which was commercially available and being used for the correction of Rhytids, scar contractures and dystrophic epidermolysis bullosa before the EU’s ATMP regulations came into force. Intercytex also carried out the world's first cell therapy clinical trial to induce new hair formation. Paul has sat on a variety of panels, grant funding bodies and regulatory committees. He is co-editor of the Journal of Regenerative Medicine, a co-Director of the Doctoral Training Centre in Regenerative Medicine at Manchester University and Industrial Director of Regener8.
Predrag has 16 years experience in finance and business development with an in-depth knowledge of FMCG and other industries in multinational and multicultural environments. He has experience in auditing, financial consulting and business advisory services.
He started his career working for BDO, the fifth largest audit house in Serbia, as a representative of audit house Arthur Andersen. He has significant experience working with some of the biggest domestic and international companies.
Currently, he is responsible for the Serbia group for financial reporting, Fresenius Medical Care (statutory and US GAAP/IFRS from 2016), finance, accounting, tax, treasury, controlling, system & process improvements, SAP/software, IT hardware and infrastructure.
Lecturer & Mentor, Judge Business School, University of Cambridge
Tony is an entrepreneur with exits and an authority on corporate innovation, entrepreneurship, start-ups, scaling and leveraging emerging technologies, capabilities and business models including circular economy. He is especially focused on Environment, Healthcare, Social Impact, purpose driven organisations.
He is currently a Board Member & Venture Partner of UNDP, International Trade Centre & Pfizer backed sustainability venture accelerator Accelerate2030 in Geneva that scales the impact of companies working towards positive social and environmental change aligned with the UN Sustainable Development Goals.
As an entrepreneur in residence with UK government’s Global Entrepreneur Programme he specialises in environmental, social impact, renewable energy and healthcare innovation combining positive impact with high commercial performance and access to finance for growth and scale at a global level.
Tony is active in research and academia and is a visiting lecturer and mentor at the University of Cambridge; Judge Business School, Entrepreneurship Centre, University of Cambridge; Department of Engineering, Institute for Manufacturing, INSEAD and the University of Cairo with focus on the UN SDG’s and the circular economy.
His corporate experience includes being a member of the Executive Board of T-Mobile International & Deutsche Telekom's corporate venturing T-Ventures as global EVP Business Development & Innovation and Group Managing Director of Bauer Digital for the €1.4bn M&A and post- merger integration of EMAP PLC. He has held senior international leadership positions in FMCG brand marketing (Nestle, Diageo).
His start-up and growth stage experiences include being the co-founder of mobile entertainment company Mobilephonia, leading the turnaround and sale of digital services agency Bluewave (Maersk portfolio) and the leadership team for an $800m IPO (NASDAQ: ACOM). He was co-founder and founding investor of accelerator Springboard (acquired by Techstars) and founder of Health-Tech Company Dupl (IP sale Optima), which provides context to biometric sensor data.
He is an investor and board advisor in mobile technology, digital media, nanotechnology, sustainability, CleanTech, HealthTech and software ventures with M&A exits to Oracle, Piksel, Nokia and Opentext.
Tony has an MBA from Henley Business School specialising in corporate venturing, BSc (Hon) Physics & Electronic Systems, from Brunel University, certified Neuro-Linguistic Programming (NLP) practitioner from University California, Santa Cruz and the Technische Universiteit Delft in Circular Economy.
Miloš Matić is Senior Venture Associate at ICT Hub Venture, first privately owned early-stage venture capital fund in Serbia. Miloš is in charge of funds operations, portfolio management and development, mapping and sourcing of startups from the SEE region. As a part of ICT Hubs’ ecosystem, Miloš is in charge of building the entrepreneurship community and mentoring local startups.
He is the part of the Google Launchpad Mentor Programme, a global community of verified mentors for startups, and he is called to be a mentor for many other local and regional programs such as Biosense Accelerator, Startup Academy in Montenegro, Startup Week in North Macedonia and many others. Miloš is also Ambassador and Advisor for Global Startup Awards competition and entrepreneur himself.
Additionally, Miloš is a member of two working groups of Digital Initiative Serbia and Ministry of innovation and technology development of the Government of Serbia, both aiming to further develop the startup ecosystem and capital markets in Serbia.
He previously worked for UNDP and Microsoft Development Center Serbia.
Dr Mellad is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes. As CEO and co-founder of Start Codon, he aims to identify and recruit the most disruptive healthcare start-ups across Europe, seed-fund them and drive their success. Previously, he was the CEO of Cambridge Epigenetix which has developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. While at Cambridge Epigenetix, Jason transformed the research tools company into a leading liquid biopsy player and led two successful fundraisers (Series B and C) for a total of $51m. Prior to joining Cambridge Epigenetix, Jason was a Business Development Manager for Horizon Discovery’s diagnostics division, being responsible for developing and launching new reference standards for genomic clinical assays. Jason obtained his PhD in Medicine from the University of Cambridge with a focus on the molecular mechanisms regulating vascular remodelling within coronary artery bypass grafts.
Vladimir has more than 18 years of experience in Serbian financial markets. He has a proven track record in the creation of legal and institutional frameworks (National Bank of Serbia, Serbian Central Securities Depository), but also as an active participant in financial markets (CEO of FIMA International-brokerage, Portfolio Manager of the FIMA Proactive fund).
Vladimir has been a managing partner and CEO of the WM Equity Partners since its incorporation. He has participated in numerous corporate finance activities (access to finance to Serbian SMEs and Start-ups), M&A mandates and restructuring procedures. He obtained his bachelor and master’s degree from the Belgrade Faculty of Economics and PhD in Public Finance on the Faculty of Political Sciences. Since 2006 he has been a CFA charter-holder.
I am an innovation professional who has spent many years developing and delivering innovation and ideas in a range of different companies. I have a lot of experience in idea management and project delivery and my consulting business provides support in these areas.
Dr Richard Saldanha is a Managing Director at Oxquant, an advisory/consulting firm he founded in 2001. Richard is an Independent Adviser to Oxford Portfolio Advisers and lectures on statistical machine learning at postgraduate level at Queen Mary University of London. Richard has over 20 years’ experience in asset management and investment banking in the areas of risk, trading and investments. He has held senior roles at several major institutions in the City of London and also managed his own hedge fund, Oxquant Capital Partners, between 2004 and 2006. Richard holds a doctorate (DPhil) in applied mathematics from the University of Oxford.
Dr. Yufang Shao, founder of Bon Opus Biosciences LLC, a caring CRO providing best value services for research grade reagents from gene to protein to antibody to life science community. Prior to Bon Opus Biosciences, Yufang worked as Principal Scientist at Roche, Nutley, NJ. Afterwards, she established Novoprotein USA site leading its marketing and sales activity from ground. Yufang has a Ph.D degree in Neurosciences in Stony Brook University and B.S degree in Fudan University. She did post-doc training at Memorial Sloan Kettering Cancer Center and Senior Scientist at the same institute working on High-throughput Screening.
Rob Shay has been the Chief Financial Officer for Seven Bridges since June, 2018 and has over 25 years of international financial leadership experience. Rob has served in multiple executive level financial roles for both private and public U.S. companies, partnering with operating leaders to drive long-term growth and improve gross margins through the efficient use of capital and process optimization. Prior to joining Seven Bridges, Rob held leading finance roles at IHSMarkit, supporting both the Energy and Automotive business portfolios. Rob also has M&A and VC fundraising experience having participated in a $1.5B acquisition and Series C raise.Rob received his undergraduate degree in Economics and Government from Bowdoin College and his MBA from the Olin School of Business at Babson College.
Consultancy and Services Manager, University of Sussex
Alex has supported start-ups and MSMEs to grow and develop for nearly 20 years’, across various industry sectors and markets between Europe, Balkans and ex CIS. As a management consultant, adviser, trainer and project manager, he shares his experience and expertise in business strategy and planning, as well as internationalisation.
He has developed considerable experience within the ICT and digital industries, including several related verticals, including renewables, health-tech, software development and AI, environmental and clean-tech. Alex has cooperated as trainer and coach with Inspiral (Sheffield Cultural Industries Quarter Incubator), Sheffield Hallam University Science and Technology Park, and currently provides training and mentoring support to Western Balkans start-ups in cooperation with the Impact Hub, with the Belgrade Business Incubator of Technical Faculties (main country science and tech park), and is a jury member at the Belgrade Venture Forum.
Alex has also contributed to MSME and start-up growth via cooperating with UK Trade & Investment (now DIT), EBRD, European Training Foundation, EU DG NEAR, OECD and various government agencies throughout Western Balkans. He currently works with the University of Sussex as Consultancy and Services Manager, and holds an LLB Hons from La Sapienza University (Rome), an MSc International Business and second MSc in Marketing Management from the Sheffield Business School.
Michael Spiegler founded MJS Consulting in 2012 after multiple successful sales roles at Fortune 500 pharmaceutical and medical device companies. MJS Consulting specializes in assisting medical device companies establish distribution networks and formulate to-market strategies both domestically and internationally. The clients range from pre-market startups to well-established multinational organizations. Additionally, he founded MPM in 2017 to help device, biotech, digital, and Life Science companies with all aspects of digital marketing and brand strategy.
Holding a degree in Quality Control of Medicines from the Federico II University of Naples and an MBA from Business School Lausanne, Valentina is a motivated and ambitious professional that has 11 years' experience in the pharma industry. Valentina has spent most of her career in Novartis in roles of increasing responsibility within quality assurance and manufacturing areas of drug development and commercial business units. After her MBA she decided to join the “start-up like” company focused on multiple therapeutic areas as well as orphan diseases, Idorsia where she can contribute to moving projects forward from the development to commercial phase. She is positive, creative and inspiring with the passion for continuous improvement and problem solving. Traveler. Painter. Art and books lover.
Innovation and Business Development Director, ICT Hub
Dušan Vukanović is the Innovation and Business Development Director at ICT Hub, a leading Serbian company providing innovation consultancy services to large corporations. At ICT Hub, which he joined in 2015, Dušan has helped to build an ecosystem in which corporations and technology startups partner and collaborate. As a lead consultant, his primary role is to design and deliver programs that support innovation processes in large corporations. As a startup mentor he has participated in numerous programs supporting technology startups (EU Funded FRACTALS, and World Bank funded Pioneers of the Balkans), where he was mentoring startups from Italy, Greece, Slovenia, Croatia and Serbia.
Before joining ICT Hub, Dušan has been successfully running a private consulting business (Cromer Group, 2007-2014) which focused on organisational development and strategic communications. Between 1999 and 2006, Dušan worked for USAID funded National Democratic Institute for International Affairs on different activities supporting political process and government institutions. Between 2005 and 2007 he was Executive Director of an authentic local NGO that was a hub for development and networking of young political and civic leaders from Serbia and the Western Balkan Region (Center for the Development of Parliamentary Debate).
Since 2016, Dušan has been the co-founder of a technology startup in the area of people analytics (One Assessment).
Between 2012 and 2014 Mr. Vukanović was a member of the Managing Board of the Association of Management Consultants of Serbia.
He is a member of the Belgrade chapter of the Serbian Entrepreneurs, a pay-it-forward global network of entrepreneurs fostering the Serbian startup ecosystem. In 2016 he published “Manual for Launching a Technology Startup in Serbia”. Dušan studied Politics and International Relations at the London School of Economics.
Yaming Wang, PhD is the Founder and Managing Director of Alphabet Health. On a mission to bring the latest innovations in the biotech/pharmaceutical world to the people who urgently need them, Alphabet Health is a marketing and communications agency that takes an integrated partnership approach to stakeholder engagement within the healthcare industry. He and his team of experts strive to blend science, medicine and technology to make a difference and improve the lives of patients.
For over 10 years, Yaming has worked seamlessly alongside brand teams in a plethora of biotech/pharmaceutical companies across the globe and has gained a deep knowledge into pharmaceutical marketing strategy, medical education and scientific communications.
Yaming earned his PhD in Molecular Oncology and Immunology from New York University School of Medicine in New York City, where he studied molecular signaling pathways underlying oncogenesis in a variety of tumors and immune responses to pathogens. His research yielded multiple publications in top-tier journals including Nature and Immunity.
Ashlee Wisdom is the Founder & CEO of Health In Her HUE, a digital and IRL platform that leverages the power of technology, media and community to improve health outcomes for Black women. As a public health professional, Ashlee is a champion for health equity, and is passionate about prioritizing equity in healthcare innovation. Ashlee currently works for an advisory firm, Junto Health, where she is the Program Director for the Strategic Ventures Group, an exclusive consortium of nationally-ranked health systems who are pioneering a collaborative approach to strategic venture investing. Ashlee obtained her BS in Psychology with a minor in Biology from Howard University, and an MPH with a concentration in Healthcare Policy & Management from NYU.